Generic dossier
Brimonidine tartrate
0.33% · Gel · Persistent facial erythema
Product data
- Strength
- 0.33%
- Dosage form
- Gel
- Dosage-form group
- Topical
- Therapeutic area
- Persistent facial erythema
- Market
- EU/US
- Exclusivity signed
- UK
- Status
- Dossier target · May 2027
- Development status
- 9-month stability completed; pilot bio planned Sep 2026
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23